Skip to main content
. 2016 Jun 28;8(18):770–778. doi: 10.4254/wjh.v8.i18.770

Figure 4.

Figure 4

Forest plot for 1-year progression-free survival after yttrium-90 radioembolization and transarterial chemoembolization. Y90RE showed a statistically significant benefit in terms of higher progression-free survival rate assessed at 1 year (OR = 1.67, 1.10-2.55, P = 0.02). There was no evidence of heterogeneity among individual studies (P = 0.66; I2 = 0%). Y90RE: Yttrium-90 radioembolization; TACE: Transarterial chemoembolization; OR: Odds ratio.